NCT05345509进行中（未招募）1 期
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- AUClast of IVL3003
研究概览
简要总结
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
详细描述
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the study site).
- •Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg for males and ≥50.0 kg for females.
- •Male subjects who are sexually active with a same-sex partner must be willing to use a condom until study exit.
- •Male and female subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
- •Willing to abstain from use of non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin, meloxicam, etc. from screening until study exit.
- •Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol specific study procedures.
排除标准
- •Any clinically significant abnormal finding at physical examination at screening.
- •Clinically significant abnormal laboratory test results or positive serology test results for human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus at screening.
- •Positive pregnancy test at screening or Day -1 or lactating female subject.
- •Positive drug or alcohol screen at screening or Day -
- •Any history of malignancy or neoplastic disease.
- •History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, hypersensitivity, angioedema) to donepezil, piperidine derivatives, dimenhydrinate or derivatives, benzatropine or derivatives, or other related drugs, or to any excipient present in the formulation for any study drug.
- •Presence of hereditary disorders including galactose intolerance, lactase deficiency, and glucose-galactose malabsorption (for Part B only).
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin >1.5x the upper limit of normal (ULN) at screening or Day -
- •Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -
- •Clinically significant ECG abnormalities (QTc >450 ms or PR interval >220 ms) or vital sign abnormalities (systolic blood pressure <90 or >140 mmHg, diastolic blood pressure <40 or >90 mmHg, or heart rate <50 or >100 bpm) at screening or Day
- •History of significant bradycardia or atrioventricular (AV) block.
- •History of significant asthma (except for fully resolved childhood asthma) or chronic obstructive pulmonary disease (COPD).
- •History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%).
- •History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 month, or use of codeine within 3 months prior to screening.
- •Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
- •Consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day).
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
研究组 & 干预措施
Aricept Tablet
Active Comparator
Aricept Tablet, QD, PO
干预措施: Aricept Tablet (Drug)
IVL3003 (A mg)
Experimental
SC, Single Dose
干预措施: IVL3003 (Drug)
IVL3003 (B mg)
Experimental
SC, Single Dose
干预措施: IVL3003 (Drug)
IVL3003 (C mg)
Experimental
SC, Single Dose
干预措施: IVL3003 (Drug)
IVL3003 (Dmg)
Experimental
Intramuscular
干预措施: IVL3003 (Drug)
IVL3003 (Emg)
Experimental
Intramuscular
干预措施: IVL3003 (Drug)
结局指标
主要结局
AUClast of IVL3003
时间窗: Pre-dose, up to 1month
Area under the concentration-time curve from time zero to last
AUCinf of IVL3003
时间窗: Pre-dose, up to 1month
Area under the concentration-time curve from time zero to infinity
AUCinf of Aricept
时间窗: Pre-dose, up to 1month
Area under the concentration-time curve from time zero to infinity
AUClast of Aricept
时间窗: Pre-dose, up to 1month
Area under the concentration-time curve from time zero to last
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001Androgenetic AlopeciaNCT04945226Inventage Lab., Inc.40
招募中
1 期
A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.Alcohol DependenceMultiple SclerosisNCT05620940Inventage Lab., Inc.40
招募中
1 期
Study of IBI323 in Patients With Advanced MalignanciesAdvanced MalignanciesNCT04916119Innovent Biologics (Suzhou) Co. Ltd.322
已完成
3 期
Study of Biostate® in Children With Von Willebrand DiseaseVon Willebrand DiseaseNCT01213446CSL Behring17
进行中（未招募）
3 期
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesPrimary Immune DeficiencyNCT04640142Octapharma50